Mitogen-activated
protein kinase (MAPK) are ubiquitous regulators of many cellular
functions including cell proliferation, cellular growth, inflammatory responses
to stress signals and cell differentiation. MAPK pathway, involves three main
kinases, Raf, MEK and ERK, has emerged as a novel target for the development of
new cancer therapies with reduced side-effects.
MAPK inhibitors are being developed as small molecules, for
the treatment of various types of cancer. They have also showed additional
benefits with high effectiveness at lower concentrations in comparison to the
ATP-competitive inhibitors, for the cancer therapy.
Request to Get the Sample Pages at:
Mereo BioPharma Group plc is in the process of developing
Acumapimod as an oral p38 MAPK inhibitor for the treatment of acute
exacerbations of chronic obstructive pulmonary disease (AECOPD). eFFECTOR
Therapeutics Inc., Genentech Inc., and Kura Oncology Inc. are some other
companies having pipeline of MAPK inhibitors.
Access Detailed Report Summary: https://www.pharmaproff.com/report/mapk-inhibitors-therapeutics
The report provides a comprehensive understanding of the
pipeline activities covering all drug candidates under various stages of
development, with detailed analysis of pipeline and clinical trials. Pipeline
analysis of drugs by phases includes product description and development
activities including information about clinical results, designations,
collaborations, licencing, grants, technology and others.
